SuperworthBiomarin Pharmaceutical BMRN
- Market cap
- $10.8B
- PE
- 151×
- 6y median 70.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.2×
- EV/EBIT
- 25.8×
- Revenue, 12 months
- $3.4B
- +11% on a year ago
- Net margin
- 2.1%
- Free cash flow yield
- 6.8%
Biomarin Pharmaceutical trades at 151× trailing earnings, pricier than 69% of the last ten years. Revenue was $3.4B over the last twelve months, up 11% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $581.3M+15% | $646.2M+20% | $648.8M+9% | $712M+20% | $745.7M+28% | $747.3M+16% | $745.1M+15% | $825.4M+16% | $776.1M+4% | $874.6M+17% | $766.2M+3% | $989.7M+20% | |
| Cost of revenue | $128M+10% | $137.9M+8% | $125.2M−8% | $130.5M−0% | $188.5M+47% | $136.1M−1% | $151.6M+21% | $150.1M+15% | $140.1M−26% | $275.7M+103% | $195M+29% | $202.8M+35% |
| Gross profit | $453.3M+17% | $508.3M+24% | $523.7M+14% | $581.6M+25% | $557.3M+23% | $611.2M+20% | $593.6M+13% | $675.3M+16% | $636M+14% | $598.9M−2% | $571.2M−4% | $786.9M+17% |
| R&D | $191.3M+21% | $206.3M+19% | $205M+19% | $183.8M+4% | $184.9M−3% | $173.5M−16% | $158.7M−23% | $161.3M−12% | $409.5M+122% | $192.4M+11% | $178.8M+13% | $207M+28% |
| SG&A | $215.8M−1% | $259.5M+6% | $225.9M+7% | $263M+28% | $253.5M+18% | $266.6M+3% | $206.1M−9% | $232.3M−12% | $268.4M+6% | $446.2M+67% | $258.3M+25% | $395.5M+70% |
| $30.5M | $27.3M | $88.5M+42% | $120.5M+84% | $113.9M+273% | $161.4M+492% | $223.9M+153% | $276.9M+130% | −$46.7M | −$44.6M | $129.6M−42% | $110.9M−60% | |
| Interest expense | $3.8M−19% | $6.1M+68% | $3.5M−4% | $3.6M−5% | $3M−22% | $2.6M−58% | $2.9M−19% | $2.7M−25% | $2.6M−13% | $2.8M+8% | $15M+423% | $63.3M+2263% |
| Pre-tax income | $41.7M | $19.3M | $105.5M+86% | $132.1M+87% | $134.4M+223% | $169.6M+778% | $238.1M+126% | $297.9M+125% | −$26.3M | −$27.2M | $141.2M−41% | $61.4M−79% |
| $1.3M−73% | −$1M−94% | $16.9M+186% | $25M+69% | $28.4M+2097% | $44.7M | $52.4M+210% | $57.3M+130% | $4.4M−84% | $19.4M−57% | $35.7M−32% | $16.6M−71% | |
| Net income | $40.4M | $20.4M | $88.7M+74% | $107.2M+91% | $106.1M+163% | $124.9M+513% | $185.7M+109% | $240.5M+124% | −$30.7M | −$46.6M | $105.5M−43% | $44.8M−81% |
| $0.21 | $0.11 | $0.46+70% | $0.55+90% | $0.55+162% | $0.63+473% | $0.95+107% | $1.23+124% | −$0.16 | −$0.24 | $0.54−43% | $0.23−81% | |
| 191.2M+3% | 181.4M−3% | 199.3M+3% | 200.5M+3% | 197.1M+3% | 196.8M+9% | 196.5M−1% | 197.1M−2% | 192M−3% | 192.2M−2% | 197.7M+1% | 194.5M−1% |
Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 17 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY09 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q2 FY19: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| JAZZJazz Pharmaceuticals | $13.9B | 14.6× | 20.2× | 3.0× | +13% | 20.4% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $6.9B | 60.3× | 33.0× | 7.8× | +25% | 15.0% |
Investors who own it
Investors we follow who held Biomarin Pharmaceutical at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors1.2% of portfolioadded
More on Biomarin Pharmaceutical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .